From the Desk of the CEO

One of the principal strategies used to mitigate gastrointestinal bleeds (GIBs) in critically ill patients is to use stress ulcer prophylaxis (SUP) treatments, which mainly include proton pump inhibitors (PPIs) and histamine 2 receptor antagonists (H2RAs). Over the last two decades there has been considerable flux in the consensus between clinical guidelines as to which agent is preferred.

Corey Diamond, PharmD

The United States Pharmacopeia (USP) has finally released its updated Chapter <797> revisions. These revisions were written over the past 22 months while USP considered appeals filed by stakeholders.

Joey Sweeney, PharmD

Even as opioid overdose deaths have reached record highs during the COVID-19 pandemic, patients being treated for overdose in U.S. emergency departments (EDs) didn’t receive lifesaving medications before discharge, suggests a new study published in the Annals of Emergency Medicine.

Loren Bonner

A new study conducted by Oskotsky and colleagues in JAMA Network Open’s November 2021 issue found an association suggesting that patients with COVID-19 who take selective serotonin reuptake inhibitor (SSRI) antidepressants—specifically fluoxetine hydrochloride and fluvoxamine maleate—are less likely to experience severe forms of COVID-19 requiring hospitalizations resulting in death.

Clarissa Chan, PharmD

Trending Topics in Health-System Pharmacy

APhA Staff